#1 Clinical Trials Search in Europe

Study on Alzheimer’s Disease Using Flortaucipir (18F) for Early Diagnosis in At-Risk Patients

2 1 1

What is this study about?

This clinical trial is focused on studying Alzheimer’s Disease, a condition that affects memory and thinking skills. The study will use a special imaging agent called 18F-Flortaucipir, which is a solution for injection. This agent helps in visualizing certain brain changes associated with Alzheimer’s Disease. The purpose of the study is to explore the relationship between early brain changes and the risk of developing Alzheimer’s Disease in the future.

Participants in the study will receive an injection of 18F-Flortaucipir and undergo various imaging tests, such as MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans. These tests will help researchers understand how early changes in the brain, particularly in a small area called the locus coeruleus, are linked to Alzheimer’s Disease. The study will also look at how these changes affect thinking and memory over time.

The study will take place over several years, with follow-up assessments at 12 and 24 months to monitor any changes in brain function and cognitive performance. By examining these early brain changes, researchers hope to improve the understanding of Alzheimer’s Disease and potentially aid in its early diagnosis. Participants will be divided into groups based on certain genetic factors, and their results will be compared to see if there are differences in how the disease progresses.

1 joining the study

Upon joining the study, eligibility is confirmed based on criteria such as age, cognitive assessment, and health status.

Consent is required before any study-related procedures begin.

2 initial assessment

An initial assessment is conducted to establish baseline measurements. This includes cognitive tests and evaluations of visual and motor skills.

3 administration of 18F-Flortaucipir

The medication 18F-Flortaucipir is administered as a solution for injection through an intravenous route.

This step is crucial for imaging procedures that follow.

4 imaging procedures

Imaging techniques such as functional MRI and structural MRI are used to assess brain regions of interest.

These procedures help in understanding the relationship between brain function and Alzheimer’s disease risk.

5 oculometry and pupillometry tests

Tests are conducted to measure eye movements and pupil responses.

These tests provide additional data on brain function and are repeated at various intervals.

6 follow-up assessments

Follow-up assessments occur at 12 and 24 months to monitor changes over time.

These assessments include repeated imaging and cognitive tests to track any progression or changes.

7 data analysis and conclusion

Data collected throughout the study is analyzed to evaluate the effectiveness of biomarkers in predicting Alzheimer’s disease risk.

The study aims to improve early diagnosis and understanding of Alzheimer’s disease.

Who Can Join the Study?

  • Must be 60 years old or older.
  • Must be a participant in the INSPIRE-T cohort (a group of people being studied).
  • Must have a normal cognitive assessment, meaning their thinking and memory are normal.
  • Must have a MMSE score of 27 or higher out of 30. The MMSE, or Mini-Mental State Examination, is a test that checks mental functions like memory and understanding.
  • Must have normal visual abilities, whether with or without glasses or contact lenses.
  • Must have normal motor skills, meaning they can move normally.
  • Must provide free, informed, and written consent. This means they agree to participate after understanding the study, and they sign a form to confirm this.
  • Must be affiliated with or benefiting from a social security scheme, which means they have some form of social security coverage.
  • For participants in the ApoE4 group only: Must have the ApoE4 allele. This is a specific version of a gene related to the ApoE protein, identified as part of the INSPIRE project.

Who Cannot Join the Study?

  • Individuals who do not have a diagnosis of Alzheimer’s Disease cannot participate. Alzheimer’s Disease is a condition that affects memory and other mental functions.
  • Participants must be within a certain age range, typically adults and older adults.
  • Both males and females are eligible to participate, so gender is not a reason for exclusion.
  • Individuals who are considered part of a vulnerable population, such as those who cannot give consent or are at higher risk, are not included in this study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Toulouse Toulouse France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
01.10.2024

Trial locations

Investigated drugs:

LocusTau is a medication being studied to understand its effects on biomarkers related to the locus coeruleus nucleus. This study aims to explore how these biomarkers are linked to early tau pathology, cognitive function, and the risk of developing Alzheimer’s disease. The goal is to determine if these biomarkers can help in diagnosing Alzheimer’s disease at its earliest stages.

Investigated diseases:

Alzheimer’s Disease – Alzheimer’s Disease is a progressive neurological disorder that leads to the degeneration and death of brain cells. It is characterized by a gradual decline in memory, thinking, and reasoning skills. As the disease progresses, individuals may experience confusion, mood changes, and difficulty with language and daily tasks. The progression of Alzheimer’s involves the accumulation of abnormal protein deposits in the brain, such as amyloid plaques and tau tangles, which disrupt cell function. Over time, this leads to significant brain shrinkage and loss of cognitive abilities. The disease typically affects older adults, but early-onset forms can occur in younger individuals.

Trial ID:
2023-507668-38-00
Protocol code:
RC31/23-0371
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer’s disease patients: Long-term safety evaluation

    Recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Croatia Czechia France Greece Hungary +5

  • A study testing trontinemab compared to placebo in patients with early Alzheimer’s disease including mild cognitive impairment and mild dementia

    Recruiting

    3 1 1
    Investigated drugs:
    Denmark France Germany Italy Poland Spain